Academic researchers in Massachusetts believe the standard BCG (bacillus Calmette-Guérin) vaccine could have a remarkable second use: a treatment to reverse advanced type 1 diabetes.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh